SFA — Sopharma AD Share Price
0.000.00%
Last trade - 00:00- BGN1.00bn
- BGN1.27bn
- BGN1.89bn
- 49
- 56
- 52
- 51
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 12.39 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -11.42% | ||
| Dividend Yield (f) | 3.6% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.25 | ||
| Price to Tang. Book | 1.35 | ||
| Price to Free Cashflow | 147.68 | ||
| Price to Sales | 0.51 | ||
| EV to EBITDA | 9.24 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 8.43% | ||
| Return on Equity | 10.45% | ||
| Operating Margin | 4.07% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | BGNm | 1,293.17 | 1,450.2 | 1,615.66 | 1,675.22 | 1,894.71 | 1,988.93 | 1,883.8 | 9.75% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +228.4 | -64.18 | +84.35 | +37.52 | -1.44 | -38.62 | +8.7 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sopharma AD, formerly Sopharma AD Sofia, is a Bulgaria-based company engaged in the generic pharmaceutical industry. The Company specializes in the production and trade of medical substances and finished drug forms, as well as research and development in the field of medical products. Through the ampoule plant, tablet plant and the plant in Vrabevo it produces medicines, such as analgesics, antipyretics, cardiovascular medicines as well as drugs for respiratory disease treatment, among others. The Company offers its products under the brand Tribestan, Nivalin and Tabex, among others. In addition, it specializes in the gamma-sterilization of medical materials. It is the parent company of Sopharma Group and operates domestically and abroad in such countries as Russian Federation, Poland, Ukraine, Serbia, the United States and the United Kingdom, among others.
Directors
- Ognian Donev CHM (61)
- Vesela Stoeva VCH (55)
- Boris Borisov CFO
- Yordanka Petkova CAO (54)
- Ivan Badinski DRC
- Ognyan Palaveev DRC (69)
- Andrey Breshkov IND (46)
- Aleksandar Tchaouchev IND (53)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- November 15th, 1991
- Public Since
- January 20th, 1998
- No. of Employees
- 4,834
- Sector
- Food & Drug Retailing
- Industry
- Consumer Defensives
- Exchange
- Bulgarian Stock Exchange
- Shares in Issue
- 165,729,065
- Address
- rayon Nadezhda, ul. Iliensko Shose No16, SOFIA, 1220
- Web
- https://www.sopharmagroup.com/
- Phone
- +359 28134523
- Auditors
- Baker Tilly Klitou
Upcoming Events for SFA
September 2024 Sopharma AD Corporate Sales Release
Q3 2024 Sopharma AD Earnings Release
October 2024 Sopharma AD Corporate Sales Release
November 2024 Sopharma AD Corporate Sales Release
December 2024 Sopharma AD Corporate Sales Release
January 2025 Sopharma AD Corporate Sales Release
Similar to SFA
CBA Asset Management AD
Bulgarian Stock Exchange
FAQ
What is the Sopharma AD share price?
As of Today at 23:22 UTC, shares in Sopharma AD are trading at BGN6.04. This share price information is delayed by 15 minutes.
How has the Sopharma AD share price performed this year?
Shares in Sopharma AD last closed at BGN6.04 and the price had moved by -1.63% over the past 365 days. In terms of relative price strength the Sopharma AD share price has underperformed the FTSE Global All Cap Index by -11.75% over the past year.
What are the analyst and broker recommendations for Sopharma AD?
The overall consensus recommendation for Sopharma AD is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Sopharma AD dividend yield?
The Sopharma AD dividend yield is 1.49% based on the trailing twelve month period.
Does Sopharma AD pay a dividend?
Last year, Sopharma AD paid a total dividend of BGN0.09, and it currently has a trailing dividend yield of 1.49%. We do not have any data on when Sopharma AD is to next pay dividends.
When does Sopharma AD next pay dividends?
We do not have data on when Sopharma AD is to next pay dividends. The historic dividend yield on Sopharma AD shares is currently 1.49%.
How do I buy Sopharma AD shares?
To buy shares in Sopharma AD you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Sopharma AD?
As of the previous close price of BGN6.04, shares in Sopharma AD had a market capitalisation of BGN1.00bn.
Where are Sopharma AD shares listed?
Here are the trading details for Sopharma AD:
- Country of listing: Bulgaria
- Exchange: BLG
- Ticker Symbol: SFA
What kind of share is Sopharma AD?
Based on an overall assessment of its quality, value and momentum Sopharma AD is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Sopharma AD share price forecast for 2024?
The analyst consensus target price for shares in Sopharma AD is BGN7.10. That is 17.55% above the last closing price of BGN6.04.
Analysts covering Sopharma AD currently have a consensus Earnings Per Share (EPS) forecast of BGN0.46 for the next financial year.
Find out moreWhat is the trend in the Sopharma AD share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sopharma AD. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -8.7%.
As of the last closing price of BGN6.04, shares in Sopharma AD were trading -0.93% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Sopharma AD PE Ratio?
The Sopharma AD PE ratio based on its reported earnings over the past 12 months is 12.39. The shares last closed at BGN6.04.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Sopharma AD?
Sopharma AD's management team is headed by:
- Ognian Donev - CHM
- Vesela Stoeva - VCH
- Boris Borisov - CFO
- Yordanka Petkova - CAO
- Ivan Badinski - DRC
- Ognyan Palaveev - DRC
- Andrey Breshkov - IND
- Aleksandar Tchaouchev - IND